Background and study aim : Chronic Hepatitis C virus (HCV) infection is typically characterized by slowly progressive hepatic fibrosis. However, it is recognized that some patients do not progress while others rapidly develop significant fibrosis. Immune response mechanism in the control of viral replication and persistence in HCV induced liver disease has been well documented. Solute carrier 11a1 (SLC11A1) plays an immunomodulatory role in influencing macrophage activation status and the T helper 1/T helper 2 biases. It modulates the susceptibility to infectious/autoimmune diseases. The study aimed to: Analyze the possible involvement of polymorphism in the promoter regions of the SLC11A1 gene in the susceptibility for chronic hepatitis C infection and the progression of fibrosis in these patients.
Patients and methods:
This study included 138 subjects. They were classified into 2 groups: Group I that included 69 matched apparently healthy persons and Group II that included 69 chronic hepatitis C patients (Child A) and was divided into 2 subgroups: Group (IIA): It included 35 chronic hepatitis C patients without fibrosis and Group (IIB): It included 34 chronic hepatitis C patients with fibrosis. All individuals were subjected to: Full history taking, complete physical and clinical examination, abdominal ultrasound, fibroscan, routine laboratory investigations, viral markers and determination of SLC11A1 promoter gene polymorphism.
Results:
The present study demonstrated that no statistically significant difference was observed in the distribution of SLC11A1 genotype frequencies among patient and control groups, suggested absence of association between the presence of the polymorphism and the prevalence of disease. Moreover, chronic hepatitis C patients who had SLC11A1 2/2 genotype were significantly at decreased risk to develop fibrosis 0.2 times than those who had 3/3 genotype [OR:0.2, CI:(0.52-0.79)] suggesting that the 2/2 genotype is associated with an decreased susceptibility to develop fibrosis.
Conclusion and recommendations:
SLC11A1 gene promoter polymorphism could influence fibrosis progression in chronic hepatitis C in that the homozygous genotype 2/2 exerts a protective effect against cirrhosis development. Gene therapy may have an important role in the treatment and prognosis of HCV infection which need further studies. Chronic hepatitis C virus infection is typically characterized by slowly progressive hepatic fibrosis. However, it is recognized that some patients do not progress while others rapidly develop significant fibrosis. The major morbidity and mortality of persistent HCV infection occurs after the establishment of hepatic fibrosis and the subsequent occurrence of cirrhosis and HCC [5] . So, assessment of factors that could influence the rate of fibrotic progression is necessary.
INTRODUCTION
The pathogenesis of HCV induced hepatic injury remains unclear but the major role played by the immune response mechanism in the control of viral replication and persistence in HCV induced liver disease has been well documented [6] .
Natural resistance-associated macrophage protein 1(NRAMP1), now strictly referred to as SLC11A1 (Solute carrier 11a1) and the gene which encodes for it is recognized as having a role in the susceptibility of human and animals to a number of infections [7] .
The Slc11a1 gene product seems to have a direct antimicrobial effect, but it also has pleiotropic effects that include macrophage activation and regulation of the Th1:Th2 balance of the adaptive immune response to intracellular pathogens [8] . SlC11A1 appears to influence major histocompatibility complex (MHC) class II molecules and cytokines such as tumor necrosis factor (TNFα), interleukin (IL-1b) which regulate antigen presentation [8] .
So we aimed to analyze the possible involvement of polymorphism in the promoter regions of the SLC11A1 gene in the susceptibility for chronic hepatitis C infection and the progression of fibrosis in these patients. 
PATIENTS AND METHODS
under ultraviolet transillumination (Heralab GmbH laborgeratetransilluminator, Germany). -Three alleles 162 bp (allele 1), 152bp (allele2) and 130 bp (allele3) were identified in Egyptian population.
Statistical Analysis
All data were analyzed using SPSS 15.0 for windows (SPSS Inc., Chicago, IL, USA). Quantitative data were expressed as the mean ± SD & median (range), and the categorical data were expressed as a number (percentage). Chisquare (χ 2 ) test was used for comparison between groups (qualitative variable). A P value <0.05 was considered statistically significant, P<0.005 was considered highly statistically significant, and P>0.05 was considered non statistically significant. Odd ratio (OR) was used to estimate risk in univariate model with 95 % confidence interval. If interval contain 1, the p value of test statistics will be non-significant. Regarding Genotypes of SLC11A1 promoter gene polymorphism in chronic hepatitis C and control groups:
RESULTS
SLC11A1 promoter genotypes (3/3,2/3,2/2) represent >97% of all detected genotypes in all studied groups. The frequency of SLC11A1 2/2 genotype was significantly decreased in chronic hepatitis C group with fibrosis as compared to chronic hepatitis C group without fibrosis (Chi square (X2) was 7.6 and P value <0.05). Approximately 75%-85% of HCV-infected persons will progress to chronic HCV infection. Progression to cirrhosis is usually clinically silent and a wide range of fibrosis rates occur [5] .
The rate of progression to cirrhosis is highly variable, and is influenced by several factors, including the amount of alcohol consumption, age of initial HCV infection, HIV and HBV coinfection, and co-morbid conditions Concerning the relation of SLC11A1 promoter gene polymorphism with the development of chronic hepatitis C and liver fibrosis, we determined the frequency of SLC11A1 genotypes in chronic hepatitis C patients without fibrosis, chronic hepatitis C patients with fibrosis, and control groups using subjects homozygous for common allele as a reference group.
No statistically significant difference of SLC11A1 genotype frequencies among chronic hepatitis C patients as compared to control group was observed in Egyptian population (P value 0.24).
These results are matched with Romero et al.
[11] who investigated the possible role of the functional polymorphism located in the promoter region of SLC11A1 in the progression of fibrosis in chronic hepatitis C patients and reported an absence of the associations between SLC11A1 promoter gene polymorphism and the incidence of chronic hepatitis C.
As regards, the association of SLC11A1 gene polymorphism with the progression of liver fibrosis, we found that the frequency of SLC11A1 2/2 genotype was significantly decreased in chronic hepatitis C group with fibrosis as compared to chronic hepatitis C group without fibrosis (P value=0.01). Chronic hepatitis C patients who had SLC11A1 2/2 genotype were significantly at decreased risk to develop fibrosis 0.2 times than those who had 3/3 genotype (OR:0.2, CI:[(0.52-0.79)] suggesting that the 2/2 genotype is associated with an decreased susceptibility to develop fibrosis .
This finding is going in hand with Romero et al.
[11] who observed that the association between SLC11A1 2/2 genotype and lack of fibrosis progression achieved statistical significance as the SLC11A1 homozygous 2/2 genotype was rarely detected among patients showing advanced fibrosis but was highly represented in those with fibrosis grade (0,1) and added that patients carrying SLC11A1 allele 3 had high risk of advanced liver fibrosis, while those with SLC11A1 2/2 genotype had a protection against fibrosis progression.
Our results could be explained as SLC11A1 could regulate secretion of several cytokines such as tumor necrosis factor (TNF) and tumor growth factor (TGF-b21) which is involved in the activation of hepatic stellate cells and progression of fibrosis in chronic hepatitis C [12].
Romero et al. [11] reported that the SLC11A1 gene could modulate Kupffer cell activation with higher TNF production in individuals carrying SLC11A1allele 3.
Fritsche et al. [13] found that SLC11A1 has been associated with increased nitric oxide production and enhanced inducible nitric oxide syntheses (iNOS) in hepatocytes and macrophages. Nitric oxide has been implicated in the pathogenesis of chronic hepatitis C, mainly via peroxynitrite; a potential oxidant that is produced by the reduction of superoxide anion with nitric oxide [11] .
This mechanism could explain the advanced fibrosis found in patients carrying SLC11A1 3/3 genotype.
Furthermore, IL-8 receptor gene is in an adjacent location to the SLC11A1 gene and this chemokine has been associated with viral persistence and resistance to interferon therapy [14] .
As regards the relation of SLC11A1 gene polymorphism to the liver function tests. Our results were matched with Romero et al. [11] , who found that that there was no statistically significant difference of liver function tests between SLC11A1 3/3 genotype carriers, SLC11A1 2/3 and2/2 genotype carriers.
In conclusion, the results of our study supported the suggestion that SLC11A1 gene promoter polymorphism could influence fibrosis progression in chronic hepatitis C in that the homozygous genotype 2/2 exerts a protective effect against cirrhosis development.
Recommendation: This study draws attention to the importance of gene therapy in the prognosis of the HCV infection which needs further studies.
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